Bixalomer in Hyperphosphatemic Patients With Chronic Kidney Disease Not on Dialysis: Phase 3 Randomized Trial

• Published in: Therapeutic apheresis and dialysis Vol. 20; no. 6; pp. 588 - 597
• Main Authors: Akizawa, Tadao, Origasa, Hideki, Kameoka, Chisato, Tsukada, Junko, Kuroishi, Kentarou, Yamaguchi, Yusuke
• Format: Journal Article
• Language: English
• Published: Australia Blackwell Publishing Ltd 01-12-2016
• Subjects: Aged; Bixalomer; Chronic kidney disease; Double-Blind Method; Female; Humans; Hyperphosphatemia; Hyperphosphatemia - complications; Hyperphosphatemia - drug therapy; Male; Middle Aged; Phosphate binder; Polyamines - therapeutic use; Predialysis; Renal Insufficiency, Chronic - complications; Treatment Outcome; Bixalomer; Hyperphosphatemia; Chronic kidney disease; Phosphate binder; Predialysis
• ISSN: 1744-9979; 1744-9987
• DOI: 10.1111/1744-9987.12461

Currently, calcium‐ or metal‐containing phosphate binders are available to treat hyperphosphatemia in predialysis patients with chronic kidney disease. Bixalomer, a non‐calcium, metal‐free phosphate binder, has not been studied in these patients. We evaluated the efficacy and safety of bixalomer versus placebo for treatment of hyperphosphatemia in Japanese predialysis patients with chronic kidney disease. This multicenter, randomized, double‐blind, phase 3 trial, randomized eligible patients 1:1 to receive bixalomer or placebo for 12 weeks. Bixalomer was started at 1500 mg/day and adjusted up to 7500 mg/day depending on serum phosphorus concentrations. The primary endpoint was change in serum phosphorus concentration from baseline to end of treatment. After a 4‐week pre‐investigational period, 163 patients (bixalomer: N = 81; placebo: N = 82) were randomized. The adjusted mean change (95% confidence interval) from baseline to end of treatment in serum phosphorus was significantly greater with bixalomer (–0.78 [–0.98, –0.57] mg/dL) versus placebo (0.20 [–0.00, 0.41] mg/dL); mean difference: –0.98 (–1.27, –0.69), P < 0.001. At end of treatment, 57.5% of bixalomer‐treated patients achieved target serum phosphorus concentrations, mean serum intact parathyroid hormone and fibroblast growth factor‐23 decreased, and there were no significant changes in corrected serum calcium. The safety and tolerability of bixalomer was similar to placebo. The most common drug‐related adverse events were gastrointestinal (>24% patients per group). There was a significant increase in bicarbonate concentrations with bixalomer versus placebo (P = 0.003). Bixalomer was superior to placebo for hyperphosphatemia in Japanese predialysis patients with chronic kidney disease and may constitute a new treatment option.